Dr. Gabriel Brooks is the Chief Medical Officer and leads the clinical function for all of Solid’s neuromuscular and cardiac programs.
Dr. Brooks has served as the Chief Medical Officer for Solid Biosciences since October 2023, having previously led the Rare Disease Research Unit at Pfizer as Rare Cardiovascular Therapeutic Area Head from September 2020.
Between September 2020 and September 2023, Dr. Brooks directed the translational development of a range of precision AAV gene therapies for dilated, arrhythmogenic, and hypertrophic cardiomyopathies, at Pfizer. Dr. Brooks also served as the vice president of research and development at 4D Molecular Therapeutics from November 2018 to September 2020, where he oversaw translational development of AAV gene therapies for Anderson Fabry, as well as the first-in-human dosing of AAV gene therapies for two ophthalmologic indications (choroideremia and X-linked retinitis pigmentosa). From April 2017 to November 2018, Dr. Brooks led a successful Phase III registrational study of flurpiridaz at GE Life Sciences, and led several cardiovascular clinical trials in rare and large market indications during his time at Gilead Life Sciences between August 2015 and April 2017.
Dr. Brooks received a Bachelor of Science in Biology from Carnegie Mellon University, a Doctor of Medicine from Cornell University, and a Master of Applied Sciences of Biostatistics and Epidemiology from the University of California, San Francisco. He completed his training in Internal Medicine at Johns Hopkins Hospital, Baltimore, and fellowships in general Cardiology and Advanced Imaging at the University of California, San Francisco.
What is Gabriel Brooks' net worth?
The estimated net worth of Gabriel Brooks is at least $200.21 thousand as of October 20th, 2025. Dr. Brooks owns 33,819 shares of Solid Biosciences stock worth more than $200,208 as of December 4th. This net worth evaluation does not reflect any other assets that Dr. Brooks may own. Learn More about Gabriel Brooks' net worth.
How do I contact Gabriel Brooks?
Has Gabriel Brooks been buying or selling shares of Solid Biosciences?
Over the course of the past ninety days, Gabriel Brooks has sold $17,254.20 of Solid Biosciences stock. Most recently, Gabriel Brooks sold 2,895 shares of the business's stock in a transaction on Monday, October 20th. The shares were sold at an average price of $5.96, for a transaction totalling $17,254.20. Following the completion of the sale, the insider now directly owns 33,819 shares of the company's stock, valued at $201,561.24. Learn More on Gabriel Brooks' trading history.
Who are Solid Biosciences' active insiders?
Are insiders buying or selling shares of Solid Biosciences?
During the last twelve months, Solid Biosciences insiders bought shares 1 times. They purchased a total of 1,860 shares worth more than $9,932.40. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 31,092 shares worth more than $155,239.01. The most recent insider tranaction occured on December, 3rd when COO David T Howton sold 4,932 shares worth more than $25,202.52. Insiders at Solid Biosciences own 1.9% of the company.
Learn More about insider trades at Solid Biosciences. Information on this page was last updated on 12/3/2025.
